Condition: Systemic Lupus Erythematosus (SLE) · Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
A clinical study to explore the safety, efficacy and cell metabolic kinetics of universal CD19/20 car-t cell injection in moderate to severe refractory systemic lupus erythematosus. This study is a single arm, open, exploratory dose increasing clinical study, which aims to evaluate the safety, efficacy and cell metabolic dynamics of ct1192 cells in patients with SLE.
This description comes directly from the study's public registry record.
Qiubai Li · Professor 85726808 Ext.027 · qiubaili@hust.edu.cn
Always discuss trial participation with your own doctor first.
| Wuhan Union Hospita | Wuhan, Hubei, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07031713